Text Size
1275 studies found for:    "Melanoma"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
2 Completed Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Melanoma, Experimental;   Experimental Melanomas
Interventions: Biological: aldesleukin;   Biological: therapeutic autologous lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine phosphate
3 Completed Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Interventions: Drug: dendritic cell-gp100-MART-1 antigen vaccine;   Drug: sargramostim
4 Terminated
Has Results 		Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Melanoma, Experimental
Interventions: Drug: DMF5 Melanoma Reactive TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
5 Withdrawn Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
Conditions: Melanoma;   Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: sorafenib tosylate;   Drug: temsirolimus
6 Completed Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Intervention: Drug: dasatinib
7 Recruiting Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIB Melanoma (Locally Advanced);   Stage IIC Melanoma (Locally Advanced);   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma (Limited, Resectable)
Interventions: Drug: dabrafenib;   Drug: trametinib;   Other: laboratory biomarker analysis
8 Completed Phase II Trial of Allovectin-7® for Metastatic Melanoma
Conditions: Melanoma;   Metastatic Melanoma;   Malignant Melanoma;   Skin Cancer
Intervention: Genetic: Allovectin-7®
9 Completed Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Intervention: Drug: allovectin-7
10 Completed Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Interventions: Drug: allovectin-7;   Drug: allovectin-7/dacarbazine;   Drug: dacarbazine
11 Terminated A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Metastatic Melanoma
Intervention: Drug: 131I-TM601
12 Recruiting LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma;   BRAF Mutant Melanoma
Intervention: Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
13 Completed Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
Conditions: Stage IV Melanoma;   Recurrent Melanoma
Intervention: Biological: recombinant interferon beta
14 Active, not recruiting Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IV Melanoma
Intervention: Drug: vorinostat
15 Active, not recruiting Dinaciclib in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Mucosal Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Intervention: Drug: dinaciclib
16 Completed AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Intraocular Melanoma;   Iris Melanoma;   Lentigo Maligna Malignant Melanoma;   Recurrent Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
17 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Solar Radiation-related Skin Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis
18 Completed Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Drug: bortezomib
19 Recruiting Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: riluzole;   Drug: sorafenib tosylate;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
20 Completed Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: gp100 antigen;   Biological: tyrosinase peptide;   Biological: recombinant MAGE-3.1 antigen;   Biological: multi-epitope melanoma peptide vaccine;   Biological: incomplete Freund's adjuvant;   Drug: Montanide ISA 51 VG;   Drug: agatolimod sodium;   Other: laboratory biomarker analysis
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years